Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Índice Bovespa

US Dollar vs BRL

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Click aqui para mais gráficos Qiagen NV.

Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024

Click aqui para mais gráficos Qiagen NV.

Notícias Qiagen NV

Form SD - Specialized disclosure report
Sexta, 31 de Maio de 2024 (2 dias atrás) • Edgar (US Regulatory)

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
Quinta, 30 de Maio de 2024 (3 dias atrás) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Quinta, 30 de Maio de 2024 (3 dias atrás) • Edgar (US Regulatory)

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
Quinta, 30 de Maio de 2024 (3 dias atrás) • GlobeNewswire Inc.

QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
Quarta, 29 de Maio de 2024 (4 dias atrás) • GlobeNewswire Inc.

QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
Terça, 14 de Maio de 2024 (3 semanas atrás) • GlobeNewswire Inc.

QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
Segunda, 13 de Maio de 2024 (3 semanas atrás) • GlobeNewswire Inc.

QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
Terça, 7 de Maio de 2024 (4 semanas atrás) • GlobeNewswire Inc.

QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
Quinta, 2 de Maio de 2024 (1 mês atrás) • GlobeNewswire Inc.

QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
Segunda, 29 de Abril de 2024 (1 mês atrás) • GlobeNewswire Inc.

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
Quarta, 24 de Abril de 2024 (1 mês atrás) • GlobeNewswire Inc.

QIAGEN N.V. to release results for Q1 2024 and hold webcast
Terça, 9 de Abril de 2024 (2 meses atrás) • GlobeNewswire Inc.

Mais Notícias de Qiagen NV

BNP Paribas Issuance

3 Banken Nachhaltigkeits...

Audax Senior Loan Fund Iii

Vontobel Financial Produ...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições